Diapositiva PPT

IDNT and RENAAL Trial Results

Doubling of Creat, 16 (P=0.02) 20 (P=0.02) 23 (P=0.006) -4 (P=0.69) ESRD, or death

Doubling of Creat 25 (P=0.006) 33 (P=0.003) 37 (Pɘ.001) -6 (P=0.60)

ESRD 28 (P=0.002) 23 (P=0.07) 23 (P=0.07) 0 (P=0.99)

Death -2 (P=0.88) 8 (P=0.57) -4 (P=0.8) 12 (P=0.4)

CV Morbidity 10 (P=0.26) 9 (P=0.4) -3 (P=0.79) 12 (P=0.29) & Mortality

Losartan vs control

Irbesartan vs control

Irbesartan vs amlodipine

Amlodipine vs control

RRR (%)

Comparison of Major Endpoints

RENAAL

IDNT

Lewis EJ et al. N Engl J Med 2001;345:851-860.

Brenner B et al. N Engl J Med 2001;345:861-869.